A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis

Memorial Sloan Kettering Cancer Center (MSK)

Status: Active, not recruiting

Conditions: Histiocytosis

Treatments: Behavioral: Trail Making Test, Parts A & B; Behavioral: Symbol Span; Behavioral: Brief Test of Attention; Diagnostic Test: MR Brain Imaging; Diagnostic Test: Resting state functional MRI; Behavioral: Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog); Behavioral: The Hopkins Verbal Learning Test-Revised; Behavioral: Brief Visuospatial Memory Test-Revised; Behavioral: McGill Quality of Life Scale; Behavioral: Hospital Anxiety and Depression Scale; Behavioral: Controlled Oral Word Association Test

Study type: Observational

Funder types: Other

Identifiers

NCT03127709

17-199

Details and patient eligibility

About

The purpose of this study is to try to understand how histopcytosis can cause symptoms or problems in the brain. The tests being done in the study will look at memory and thinking as well as brain function via MRI scan.

Enrollment: 13 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age greater than or equal to 18 years.
• Fluency in English
• Diagnosis of a histiocytic disorder as determined, in the opinion of the study PI, by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
• Will undergo Standard of Care MRI.

Exclusion criteria

• Known intracranial involvement of histiocytosis (including dura, leptomeninges and brain parenchyma)
• Prior stroke or intracranial hemorrhage
• Other (non-histiocytic) intracranial neoplasm or neurological disorder deemed by the PI or Co-PI to confound neuroimaging studies (e.g., demyelinating disease)
• Existing diagnosis of a psychiatric disorder or untreated mood disturbance
• Existing diagnosis of a neurodegenerative disease, such as Alzheimer's disease
• Chronic or daily excessive alcohol consumption as determined by the PI.
• History of chronic use of corticosteroids, defined as continuous treatment for six months or longer at any time in the past
• History of severe claustrophobia or other contraindications to patient SOC brain MRI
• Prior intravenous cytarabine or cladribine
• Other current or prior treatments (e.g., high-dose chemotherapy for a different cancer) deemed by the PI or Co-PI to confound imaging studies or cognitive performance

Trial design

13 participants in 1 patient group

Participants with a histiocytic disorder diagnosis

Description:

Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.

Treatment:

Behavioral: Controlled Oral Word Association Test

Behavioral: Hospital Anxiety and Depression Scale

Behavioral: McGill Quality of Life Scale

Behavioral: Brief Visuospatial Memory Test-Revised

Behavioral: Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)

Behavioral: The Hopkins Verbal Learning Test-Revised

Diagnostic Test: Resting state functional MRI

Diagnostic Test: MR Brain Imaging

Behavioral: Symbol Span

Behavioral: Brief Test of Attention

Behavioral: Trail Making Test, Parts A & B